Several other brokerages also recently commented on AXDX. Zacks Investment Research downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, April 10th. Piper Jaffray Companies raised their price objective on shares of Accelerate Diagnostics to $22.00 and gave the company an “overweight” rating in a research report on Wednesday, February 20th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $18.75.
AXDX opened at $20.00 on Tuesday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 21.89 and a current ratio of 22.88. Accelerate Diagnostics has a 1-year low of $10.23 and a 1-year high of $24.75. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -12.35 and a beta of 3.07.
Accelerate Diagnostics (NASDAQ:AXDX) last released its quarterly earnings results on Tuesday, February 19th. The medical research company reported ($0.41) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.41). Accelerate Diagnostics had a negative net margin of 1,564.01% and a negative return on equity of 105.12%. The business had revenue of $1.80 million for the quarter, compared to the consensus estimate of $1.83 million. On average, equities analysts anticipate that Accelerate Diagnostics will post -1.79 EPS for the current year.
Hedge funds have recently made changes to their positions in the company. Reilly Financial Advisors LLC bought a new stake in shares of Accelerate Diagnostics during the 1st quarter valued at $32,000. Legal & General Group Plc raised its position in shares of Accelerate Diagnostics by 45.2% during the 4th quarter. Legal & General Group Plc now owns 5,995 shares of the medical research company’s stock valued at $69,000 after purchasing an additional 1,866 shares during the period. Metropolitan Life Insurance Co. NY raised its position in shares of Accelerate Diagnostics by 331.4% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,727 shares of the medical research company’s stock valued at $100,000 after purchasing an additional 6,704 shares during the period. Great West Life Assurance Co. Can raised its position in shares of Accelerate Diagnostics by 207.5% during the 1st quarter. Great West Life Assurance Co. Can now owns 6,395 shares of the medical research company’s stock valued at $134,000 after purchasing an additional 4,315 shares during the period. Finally, BNP Paribas Arbitrage SA raised its position in shares of Accelerate Diagnostics by 30,942.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 6,519 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 6,498 shares during the period. Hedge funds and other institutional investors own 48.90% of the company’s stock.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
Featured Article: Is a Roth IRA right for you?
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.